Pluristem Therapeutics, Inc. (PSTI)
| Market Cap | 48.52M |
| Revenue (ttm) | 234,000 |
| Net Income (ttm) | -46.81M |
| Shares Out | 32.35M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | 4.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,193 |
| Open | 1.55 |
| Previous Close | 1.58 |
| Day's Range | 1.45 - 1.65 |
| 52-Week Range | 1.31 - 4.55 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 7.31 (+387.3%) |
| Earnings Date | May 12, 2022 |
About PSTI
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PSTI stock is "Buy." The 12-month stock price forecast is 7.31, which is an increase of 387.33% from the latest price.
News
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in B...
HAIFA, Israel, March 23, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company developing novel cell therapies, today announced positive final...
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Isra...
Pluristem CEO Issues Shareholder Update
HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Exec...
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
HAIFA, Israel, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”) and Israel's largest food producer Tnuva Group (“Tnuv...
Best Penny Stocks to Buy as January Ends? 4 to Watch
Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
Best Penny Stocks to Buy Right Now? 3 For Your List in January
Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information |...
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food...
Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish...
HAIFA, Israel, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem” or “the Company”), a leading biotechnology company, and Tnuva Group (“Tnuva Group" o...
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with CO...
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its Phase II...
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Sur...
Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022
Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX ...
Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and working with othe...
Pluristem Appoints Prof. Varda Shalev MD and Mr.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Var...
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Resp...
Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank
Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursem...
Pluristem Stock Is Trading Higher As PLX-R18 Shows Regenerative Potential In Patients After Bone Marrow Transplant
Pluristem Therapeutics Inc (NASDAQ: PSTI) has reported positive topline results from Phase 1 study evaluating intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery follo...
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With CO...
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the...
HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...
World Experts in Infectious Diseases & Critical Care Form Pluristem's COVID-19 Steering Committee
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, toda...
Are Options Traders Betting on a Big Move in Pluristem Therapeutics (PSTI) Stock?
Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic...
Reports internal efficacy and safety data from first cohort Reports internal efficacy and safety data from first cohort
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...